Prognostic analysis of definitive three-dimensional radiotherapy for non-surgically resectable esophageal squamous cell carcinoma:a multi-center retrospective study (3JECROG R-01)
Wang Xin, Wang Lan, Chen Junqiang, Zhang Wencheng, Wang Xiaomin, Ge Xiaolin, Shen Wenbin, Hu Miaomiao, Yuan Qianqian, Xu Yonggang, Hao Chongli, Zhou Zhiguo, Qie Shuai, Lu Na, Pang Qingsong, Zhao Yidian, Sun Xinchen, Zhang Kaixian, Li Gaofeng, Li Ling, Qiao Xueying, Liu Miaoling, Wang Yadi, Deng Lei, Wang Wenqing, Bi Nan, Zhang Tao, Deng Wei, Li Chen, Ni Wenjie, Chang Xiao, Han Weiming, Zhou Zongmei, Liang Jun, Feng Qinfu, Wang Lvhua, Chen Dongfu, Ly Jima, Zhu Shuchai, Han Chun, Xiao Zefen
Department of Radiation Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences,Peking Union Medical College,Beijing 100021,China (Wang X,Deng L,Wang WQ,Bi N,Zhang T,Deng W,Li C,Ni WJ,Chang X,Han WM,Zhou ZM,Liang J,Feng QF,Wang LH,Chen DF,Lyu JM,Xiao ZF); Department of Radiation Oncology,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China (Wang L,Shen WB,Zhou ZG,Qiao XY,Zhu SC,Han C); Department of Radiation Oncology,Fujian Cancer Hospital/Fujian Medical University Cancer Hospital,Fuzhou 350014,China (Chen JQ); Department of Radiation Oncology,Tianjin Medical University Cancer Institute and Hospital/National Clinical Research Center for Cancer,Tianjin 300060,China (Zhang WC,Pang QS); Department 4th of Radiation Oncology,Anyang Cancer Hospital,Anyang 455000,China (Wang XM,Zhao YD); Department of Radiation Oncology,First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China (Ge XL,Sun XC); Department of Oncology,Tengzhou Central People′s Hospital,Tengzhou 277599,China (Hu MM,Yuan QQ,Hao CL,Zhang KX,Li L); Department of Radiation Oncology,Beijing Hospital,National Center of Gerontology,Beijing 100730,China (Xu YG,Li GF); Department of Radiation Oncology,Affiliated Hospital of Hebei University,Baoding 071000,China (Qie S,Liu ML); Department of Radiation Oncology,PLA Army General Hospital,Beijing 100700,China (Lu N,Wang YD)
Abstract：Objective To evaluate the survival and prognostic factors of esophageal cancer treated with definitive (chemo) radiotherapy by applying novel radiation techniques including three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiotherapy (IMRT). Methods Clinical data of 2762 patients with non-operated esophageal squamous cell carcinoma who underwent definitive (chemo) radiotherapy from 2002 to 2016 in 10 hospitals were retrospectively analyzed.The prognostic factors were also identified and analyzed. Results The median follow-up time was 60.8 months.The 1-,2-,3-and 5-year overall survival (OS) of all patients was 71.4%,48.9%,39.3%,and 30.9%,respectively.The 1-,2-,3-and 5-year progression-free survival (PFS) was 59.5%,41.5%,35.2%,and 30%,respectively.The median survival was 23 months.The median time to progression was 17.2 months.Multivariate analysis demonstrated that age,primary tumor location,clinical stage,tumor target volume,EQD2 and treatment mode were the independent prognostic factors for OS.Primary tumor location,clinical stage,tumor target volume and EQD2 were the independent prognostic factors for PFS. Conclusions In this first large-scale multi-center retrospective analysis of definitive (chemo) radiotherapy for esophageal squamous cell carcinoma in China,the 5-year OS of patients with esophageal squamous cell carcinoma is significantly improved by 3DCRT,IMRT combined with chemotherapy drugs. However,the findings remain to be validated by prospective clinical trials with high-level medical evidence.
Wang Xin,Wang Lan,Chen Junqiang et al. Prognostic analysis of definitive three-dimensional radiotherapy for non-surgically resectable esophageal squamous cell carcinoma:a multi-center retrospective study (3JECROG R-01)[J]. Chinese Journal of Radiation Oncology, 2018, 27(11): 959-964.
[1] 殷蔚伯,张力军,杨宗贻,等.放射治疗食管癌3798例临床分析[J].中华肿瘤杂志,1980,2(3):216-220. Yin WB,Zhang LJ,Yang ZY,et al. Clinical analysis of 3798 patients with esophageal cancer treated by radiotherapy[J].Chin J Oncol,1980,2(3):216-220. [2] 杨民生,王经建,万贵良,等.1160例食管癌放射治疗10年疗效[J].中华放射肿瘤学杂志,1992,1(1):31-33+69. Yang MS,Wang JJ,Wan GL,et al. Ten year survival of 1160 esophageal cancer patients treated by radiotherapy[J].Chin J Radiat Oncol,1992,1(1):31-33+69. [3] 陈延条,韦广胜,孙新东,等.840例食管癌放射治疗临床分析[J].中国放射肿瘤学,1989(3):6-8+10. Chen YT,Wei GS,Sun XC,et al. Clinical analysis of 840 patients with esophageal cancer treated by radiotherapy[J].Chin Radiat Oncol,1989(3):6-8+10. [4] 1,034例食管癌放射治疗临床分析[J].肿瘤防治研究,1978(4):46-51+84. Clinical analysis of 1034 patients with esophageal cancer treated by radiotherapy[J].Canc Res Prev Treat,1978(4):46-51+84. [5] 肖泽芬,章众,张红志,等.用三维治疗计划系统评估食管癌常规放射治疗中肿瘤剂量的分布[J].中华放射肿瘤学杂志,2004,13(4):273-277. Xiao ZF,Zhang Z,Zhang HZ,et al. Assessment of tumor dose distribution in three dimensional conformal radiotherapy treatment planning system for esophageal cancer[J].Chin J Radiat Oncol,2004,13(4):273-277. [6] Allemani C,Matsuda T,Di CV,et al. Global surveillance of trends in cancer survival 2000-14(CONCORD-3):analysis of individual recordsfor 37513025patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J].Lancet,2018,391(10125):1023-1075.DOI:10.1016/S0140-6736(17)33326-3. [7] Xi M,Xu C,Liao Z,et al. The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy[J].Radiother Oncol,2017,124(2):318-324. DOI:10.1016/j.radonc.2017.06.019. [8] Welsh J,Settle SH,Amini A,et al. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation[J].Cancer,2012,118(10):2632-2640.DOI:10.1002/cncr.26586. [9] Minsky BD,Pajak TF,Ginsberg RJ,et al. INT 0123(Radiation Therapy Oncology Group 94-05) phase Ⅲ trial of combined-modality therapy for esophageal cancer:high-dose versus standard-dose radiation therapy[J].J Clin Oncol,2002,20(5):1167-1174.DOI:10.1200/JCO.2002.20.5.1167. [10] Herskovic A,Martz K,al-Sarraf M,et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus[J].N Engl J Med,1992,326(24):1593-1598. [11] Cooper JS,Guo MD,Herskovic A,et al. Chemoradiotherapy of locally advanced esophageal cancer:long-term follow-up of a prospective randomized trial (RTOG 85-01)[J]. JAMA,1999,281(17):1623-1627. [12] Brower JV,Chen S,Bassetti MF,et al. Radiation dose escalation in esophageal cancer revisited:a contemporary analysis of the national cancer data base,2004 to 2012[J].Int J Radiat Oncol Biol Phys,2016,96(5):985-993.DOI:10.1016/j.ijrobp.2016.08.016. [13] Song T,Liang X,Fang M,et al. High-dose versus conventional-dose irradiation in cisplatin-based definitive concurrent chemoradiotherapy for esophageal cancer:a systematic review and pooled analysis[J].Expert Rev Anticancer Ther,2015,15(10):1157-1169. [14] 张安度,韩晶,韩春,等.食管鳞癌三维适形放疗剂量与疗效分析[J].中华肿瘤防治杂志,2017,24(10):703-707.DOI:10.16073/j.cnki.cjcpt.2017.10.010. Zhang AD,Han J,Han C,et al.3D-CRT dose and OS of esophageal squamous cell carcinoma[J].Chin J Cancer Prev Treat,2017,24(10):703-707.DOI:10.16073/j.cnki.cjcpt.2017.10.010. [15] 谭立君,肖泽芬,张红星,等.不能手术食管癌三维放疗与同期放化疗生存比较[J].中华放射肿瘤学杂志,2015,24(2):106-110.DOI:10.3760/cma.j.issn.1004-4221.2015.02.002. Tan LJ,Xiao ZF,Zhang HX,et al. Survival comparison of three-dimensional radiotherapy alone with concurrent chemoradiotherapy for non-surgical esophageal carcinoma[J].Chin J Radiat Oncol,2015,24(2):106-110.DOI:10.3760/cma.j.issn.1004-4221.2015.02.002. [16] Chen CY,Li CC,Chien CR.Does higher radiation dose lead to better outcome for non-operated localized esophageal squamous cell carcinoma patients who received concurrent chemoradiotherapy? A population based propensity-score matched analysis[J].Radiother Oncol,2016,120(1):136-139.DOI:10.1016/j.radonc.2016.04.042. [17] Malik V,Johnston C,O′Toole D,et al. Metabolic tumor volume provides complementary prognostic information to EUS staging in esophageal and junctional cancer[J].Dis Esophagus,2017,30(3):1-8.DOI:10.1111/dote.12505. [18] Chen Y,Zhang Z,Jiang G,et al. Gross tumor volume is the prognostic factor for squamous cell esophageal cancer patients treated with definitive radiotherapy[J].J Thorac Dis,2016,8(6):1155-1161.DOI:10.21037/jtd.2016.04.08.
2018, Vol. 27 
